期刊文献+

超声内镜对胃癌外科手术及内镜下黏膜可切除性的评价 被引量:9

Evaluation of endoscopic ultrasound in gastric cancer surgery and endoscopic mucosal resectability
暂未订购
导出
摘要 目的:阐述EUS对术前胃癌浸润深度(T分期)诊断的准确性,评价其对胃癌手术或内镜下黏膜可切除性的指导意义.方法:回顾性分析78例胃癌手术患者临床资料.患者术前均行超声内镜检查,TNM分期分析比较术前T分期与术后手术及病理结果.结果:与术后病理结果对比,EUS术前T分期总准确率为69.2%,T1、T2、T3、T4分期的准确率分别为83.3%、61.9%、40.0%和100%,对手术可切除性预测的敏感性为80.8%(63/78)其中EUS准确诊断早期胃癌5例,但1例胃黏膜下层癌,被诊断为固有肌层癌.T4期胃癌手术切除率仅为42.3%(11/26).结论:EUS对判断胃癌浸润深度准确率较高,能较准确诊断早期胃癌,对指导内镜下黏膜切除术有很大帮助.而对T4期胃癌患者,虽然诊断准确性很高,但对指导根治性手术的意义不大. AIM: To determine the diagnostic accuracy of endoscopic ultrasonography (EUS) for preoperative invasion depth of gastric cancer (T staging) and to evaluate the instructive significance of EUS in gastric cancer surgery and resectability of endoscopic mucosa. METHODS: A total of 78 patients with pathologically confirmed gastric cancer were examined by EUS before operation. Furthermore, they underwent TNM staging, and the preoperative examination results were compared with post- operative pathological results. RESULTS: Among the 78 patients, compared with post-operative pathological results, the overall accuracy of stage T of EUS was 69.2%, and the accuracy rates of T1, T2, T3 and T4 were83.3%, 61.9%, 40.0% and 100%, respectively. Meanwhile, the sensibility to the prediction of operational respectability was up to 80.8%. Five cases with early gastric cancer (EGC) diagnosed by EUS had been confirmed by the operation. However, 1 case wiht gastric submucosa cancer was diagnosed as muscularis propria (MP) cancer by EUS. Resectability of gastric cancer at stage T4 was only 42.3% (11/26). CONCLUSION: EUS bears a high accuracy rate to determine the invasion depth of gastric cancer. EUS does much favor to endoscopic mucosal resection (EMR) because EGC could be relatively accurately judged by EUS. While gastric cancer patients at stage T4 need to search new examination to confirm NM staging of gastric cancer, avoid surgery and choose a suitable therapeutic method.
出处 《世界华人消化杂志》 CAS 北大核心 2009年第16期1665-1668,共4页 World Chinese Journal of Digestology
关键词 胃癌 超声内镜 手术 内镜下黏膜切除治疗 Gastric cancer Endoscopic ultrasonography Operation Endoscopic mucosal resection
  • 相关文献

参考文献3

二级参考文献18

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2Moiseyenko VM,Ajani JA,Tjulandin SA,et al.Final results of a randomized controlled phase Ⅲ trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F)to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2005,23:Abstract 4002.
  • 3Al-Batran S,Hartmann J,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP)[J].J Clin Onc,Proc Am Soc Clin Oncol,2006,24:Abstract 4016.
  • 4Bugat R.Irinotecan in the treatment of gastric cancer[J].Ann Oncol,2003,14(Suppl 2):37 -40.
  • 5Bouche O,Raoul JL,Bonnetain F,et al.Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803[ J].J Clin Oncol,2004,22 (21):4319-4328.
  • 6Fazio N,Zampino G,Nol F,et al.Irinotecan combined with in fusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemo therapy[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4146a.
  • 7Peeters M,Van Laethem JL,Baert F,et al.Phase Ⅱ study of irinotecan+ 5FU/FA for patients with previously treated ad vanced gastric cancer[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4076a.
  • 8Bamias A,Papamichael D,Syrigos K,et al.Phase Ⅱ study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer[J].J Chemother,2003,15(3):275 -281.
  • 9Giuliani F,Maiello E,Molica S,et al.Irinotecan (CPT-11)and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients.A phase Ⅱ study of the Gruppo Oncologico dell Italia Meridionale (GOIM)[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4235.
  • 10Shah M A,Ramanathan RK,Ilson D,et al.Final results of a multicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2006,24 (18S):Abstract 4020.

共引文献382

同被引文献94

引证文献9

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部